FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049855978> ?p ?o ?g. }

• W2049855978 endingPage "337" @default.
• W2049855978 startingPage "329" @default.
• W2049855978 abstract "Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.BackgroundThe impact of cytomegalovirus (CMV) infection and disease on long-term outcome after kidney transplantation is still unsettled.MethodsBetween 1994 and 1997, 397 consecutive first kidney graft recipients and 74 retransplants were included in the study and followed prospectively until December 31, 2001. CMV infection (CMV pp65 antigenemia) and CMV disease were recorded once weekly during the first 100 days after transplantation. No CMV prophylaxis or preemptive therapy was given. In a multiple Cox proportional hazard model allowing time-dependent covariates, the effects of asymptomatic CMV infection and CMV disease, recipient age and gender, retransplantation, living donor, panel-reactive cytotoxid antibodies, acute rejection, and graft loss were tested on overall mortality beyond 100 days post-transplantation. In a similar analysis, the effect of asymptomatic CMV infection and CMV disease plus other factors were tested on death censored graft loss beyond 100 days.ResultsMedian (range) follow up time was 66.6 (<1–86.9) months. The incidence of CMV infection and disease during the first 100 days was 62.8% and 23.4%, respectively. The number of total deaths was 96 (20%), 82 occurred after the first 100 days. Independent risk factors for overall mortality beyond 100 days were asymptomatic CMV infection, RR = 2.90 (95% CI 1.61–5.22) (P = 0.001), CMV disease, RR = 2.50 (95% CI 1.31–4.79) (P = 0.006), both compared to no infection or disease, recipient age, RR = 1.066 per year (95% CI 1.048–1.084) (P < 0.001), and graft loss in the whole study period RR = 7.88 (95% CI 4.75–13.08) (P < 0.001). Asymptomatic CMV infection and CMV disease were not independent risk factors for death censored graft loss, but they significantly reduced graft survival uncensored for death, (log rank P = 0.001, respectively).ConclusionAsymptomatic CMV infection and overt CMV disease during the first 100 days increase the risk of recipient mortality beyond 100 days. This raises the question whether CMV prophylaxis should be given routinely after kidney transplantation. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. The impact of cytomegalovirus (CMV) infection and disease on long-term outcome after kidney transplantation is still unsettled. Between 1994 and 1997, 397 consecutive first kidney graft recipients and 74 retransplants were included in the study and followed prospectively until December 31, 2001. CMV infection (CMV pp65 antigenemia) and CMV disease were recorded once weekly during the first 100 days after transplantation. No CMV prophylaxis or preemptive therapy was given. In a multiple Cox proportional hazard model allowing time-dependent covariates, the effects of asymptomatic CMV infection and CMV disease, recipient age and gender, retransplantation, living donor, panel-reactive cytotoxid antibodies, acute rejection, and graft loss were tested on overall mortality beyond 100 days post-transplantation. In a similar analysis, the effect of asymptomatic CMV infection and CMV disease plus other factors were tested on death censored graft loss beyond 100 days. Median (range) follow up time was 66.6 (<1–86.9) months. The incidence of CMV infection and disease during the first 100 days was 62.8% and 23.4%, respectively. The number of total deaths was 96 (20%), 82 occurred after the first 100 days. Independent risk factors for overall mortality beyond 100 days were asymptomatic CMV infection, RR = 2.90 (95% CI 1.61–5.22) (P = 0.001), CMV disease, RR = 2.50 (95% CI 1.31–4.79) (P = 0.006), both compared to no infection or disease, recipient age, RR = 1.066 per year (95% CI 1.048–1.084) (P < 0.001), and graft loss in the whole study period RR = 7.88 (95% CI 4.75–13.08) (P < 0.001). Asymptomatic CMV infection and CMV disease were not independent risk factors for death censored graft loss, but they significantly reduced graft survival uncensored for death, (log rank P = 0.001, respectively). Asymptomatic CMV infection and overt CMV disease during the first 100 days increase the risk of recipient mortality beyond 100 days. This raises the question whether CMV prophylaxis should be given routinely after kidney transplantation." @default.
• W2049855978 created "2016-06-24" @default.
• W2049855978 creator A5008777446 @default.
• W2049855978 creator A5012961394 @default.
• W2049855978 creator A5016827674 @default.
• W2049855978 creator A5022218364 @default.
• W2049855978 creator A5052644660 @default.
• W2049855978 creator A5056683937 @default.
• W2049855978 creator A5071925529 @default.
• W2049855978 creator A5072818633 @default.
• W2049855978 creator A5075931831 @default.
• W2049855978 date "2004-07-01" @default.
• W2049855978 modified "2023-10-12" @default.
• W2049855978 title "Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival" @default.
• W2049855978 cites W1582290606 @default.
• W2049855978 cites W1975613076 @default.
• W2049855978 cites W1977046611 @default.
• W2049855978 cites W1985498707 @default.
• W2049855978 cites W1990770717 @default.
• W2049855978 cites W1993576219 @default.
• W2049855978 cites W1998810556 @default.
• W2049855978 cites W2003989707 @default.
• W2049855978 cites W2019228104 @default.
• W2049855978 cites W2052248385 @default.
• W2049855978 cites W2084606466 @default.
• W2049855978 cites W2094819570 @default.
• W2049855978 cites W2099890709 @default.
• W2049855978 cites W2103609313 @default.
• W2049855978 cites W2122865783 @default.
• W2049855978 cites W2125276796 @default.
• W2049855978 cites W2129319683 @default.
• W2049855978 cites W2131594005 @default.
• W2049855978 cites W2138924704 @default.
• W2049855978 cites W2141641417 @default.
• W2049855978 cites W2147622609 @default.
• W2049855978 cites W2152153273 @default.
• W2049855978 cites W2163813322 @default.
• W2049855978 cites W2165156474 @default.
• W2049855978 cites W2169816906 @default.
• W2049855978 cites W2331756487 @default.
• W2049855978 cites W2947922924 @default.
• W2049855978 doi "https://doi.org/10.1111/j.1523-1755.2004.00735.x" @default.
• W2049855978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15200441" @default.
• W2049855978 hasPublicationYear "2004" @default.
• W2049855978 type Work @default.
• W2049855978 sameAs 2049855978 @default.
• W2049855978 citedByCount "304" @default.
• W2049855978 countsByYear W20498559782012 @default.
• W2049855978 countsByYear W20498559782013 @default.
• W2049855978 countsByYear W20498559782014 @default.
• W2049855978 countsByYear W20498559782015 @default.
• W2049855978 countsByYear W20498559782016 @default.
• W2049855978 countsByYear W20498559782017 @default.
• W2049855978 countsByYear W20498559782018 @default.
• W2049855978 countsByYear W20498559782019 @default.
• W2049855978 countsByYear W20498559782020 @default.
• W2049855978 countsByYear W20498559782021 @default.
• W2049855978 countsByYear W20498559782022 @default.
• W2049855978 countsByYear W20498559782023 @default.
• W2049855978 crossrefType "journal-article" @default.
• W2049855978 hasAuthorship W2049855978A5008777446 @default.
• W2049855978 hasAuthorship W2049855978A5012961394 @default.
• W2049855978 hasAuthorship W2049855978A5016827674 @default.
• W2049855978 hasAuthorship W2049855978A5022218364 @default.
• W2049855978 hasAuthorship W2049855978A5052644660 @default.
• W2049855978 hasAuthorship W2049855978A5056683937 @default.
• W2049855978 hasAuthorship W2049855978A5071925529 @default.
• W2049855978 hasAuthorship W2049855978A5072818633 @default.
• W2049855978 hasAuthorship W2049855978A5075931831 @default.
• W2049855978 hasBestOaLocation W20498559781 @default.
• W2049855978 hasConcept C126322002 @default.
• W2049855978 hasConcept C141071460 @default.
• W2049855978 hasConcept C203014093 @default.
• W2049855978 hasConcept C207103383 @default.
• W2049855978 hasConcept C2522874641 @default.
• W2049855978 hasConcept C2776409557 @default.
• W2049855978 hasConcept C2777662283 @default.
• W2049855978 hasConcept C2777732132 @default.
• W2049855978 hasConcept C2777910003 @default.
• W2049855978 hasConcept C2777965375 @default.
• W2049855978 hasConcept C2778653478 @default.
• W2049855978 hasConcept C2779820661 @default.
• W2049855978 hasConcept C2780303639 @default.
• W2049855978 hasConcept C2780727368 @default.
• W2049855978 hasConcept C2911091166 @default.
• W2049855978 hasConcept C44249647 @default.
• W2049855978 hasConcept C50382708 @default.
• W2049855978 hasConcept C71924100 @default.
• W2049855978 hasConcept C90924648 @default.
• W2049855978 hasConceptScore W2049855978C126322002 @default.
• W2049855978 hasConceptScore W2049855978C141071460 @default.
• W2049855978 hasConceptScore W2049855978C203014093 @default.
• W2049855978 hasConceptScore W2049855978C207103383 @default.
• W2049855978 hasConceptScore W2049855978C2522874641 @default.
• W2049855978 hasConceptScore W2049855978C2776409557 @default.
• W2049855978 hasConceptScore W2049855978C2777662283 @default.
• W2049855978 hasConceptScore W2049855978C2777732132 @default.
• W2049855978 hasConceptScore W2049855978C2777910003 @default.

• next